FRAMINGHAM, Mass.— SCIEX, a global leader in life science analytical technologies, has appointed Chris Hagen as its new President, effective immediately. Hagen joins from Beckman Coulter Diagnostics, another Danaher Corporation business, where he most recently served as Senior Vice President and General Manager of Core Lab Specialty Solutions.
Hagen brings more than two decades of experience in healthcare and life sciences, having held senior roles in operations, marketing, and finance at Beckman Coulter, Hospira (a Pfizer subsidiary), and Abbott. At Beckman Coulter Diagnostics, he led multiple business units including Hematology, Urinalysis, Automation, and Clinical Informatics, focusing on strategic growth and innovation.
In his new role at SCIEX, Hagen will focus on driving operational and commercial excellence while advancing innovation in analytical science. “SCIEX has an amazing history with foundational impact on quantitation and characterization,” Hagen said. “I am excited to join and lead a team dedicated to launching groundbreaking innovations that empower our customers to solve some of the most impactful analytical challenges facing research scientists today.”
Hagen succeeds Joe Fox, who has been named President of Beckman Coulter Life Sciences. Fox, who led SCIEX for the past four years, reflected on the company’s evolution under his leadership. “Together, we have innovated in every area of the business, from pushing the limitations of flagship mass spec systems to breaking through in new spaces like icIEF-UV and ADME,” Fox said. “It is with great confidence that I transition the President role to Chris Hagen.”
SCIEX is part of Danaher Corporation’s portfolio of life sciences and diagnostics businesses.
